Floatz logo

Bortezomib

Relapse

Janssen Pharmaceutical K.K.Small moleculePhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

9 Active assets in the Relapse cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
University of Miami
Phase 2B
FILGRASTIM
Andrew Yee, MD
Phase 2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
Andrew Yee, MD
Phase 2CCC
Eloxatin
University of Miami
Phase 2CCC
Naltrexone
Massachusetts General Hospital
Phase 2CCC

View all 13 →

Same molecule, other indications

Bortezomib is also rated in:

non-small cell lung carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
71 / 100
View asset →
follicular lymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →